GNOM Performance — Global X Genomics & Biotechnology ETF
Data updated: 2026-07-29
GNOM returned +8.10% year to date and +61.85% over one year to May 2026. Annualised returns are +1.02% over 3 years and −10.18% over 5 years. Against its Health Care Equity category average the fund came out behind over three years but ahead over one: $100 invested three years ago grew to $103, against $131 for the category, and to $162 over one year, against $129. Volatility over the past three years was 28.86% a year. In the 12 months to May 2026 the fund lost a net $8.1M, and assets reached $55.79M.
GNOM Growth of $100
What $100 invested in Global X Genomics & Biotechnology ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | GNOM | Category average |
|---|---|---|
| 1 year (Jun 2025 – May 2026) | $162 | $129 |
| 3 years (Jun 2023 – May 2026) | $103 | $131 |
| 5 years (Jun 2021 – May 2026) | $58 | $116 |
| Since data start (Sep 2019 – May 2026) | $92 | $173 |
GNOM Trailing Returns
Total returns to May 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +8.10% |
| 1 year | +61.85% |
| 3 years (annualised) | +1.02% |
| 5 years (annualised) | −10.18% |
GNOM Annual Returns
Calendar-year total returns of Global X Genomics & Biotechnology ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–May) | +8.10% |
| 2025 | +18.36% |
| 2024 | −15.41% |
| 2023 | −7.02% |
| 2022 | −36.72% |
| 2021 | −2.21% |
| 2020 | +31.30% |
| 2019 (Sep–Dec) | +12.54% |
GNOM Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +4.9% | −0.6% | +9.6% | +3.5% | −8.6% | — | — | — | — | — | — | — |
| 2025 | +4.8% | −10.4% | −5.2% | +2.1% | −13.0% | +5.8% | +3.1% | +8.5% | +2.1% | +16.9% | +5.9% | +0.1% |
| 2024 | −7.0% | +11.1% | +3.2% | −13.3% | −5.4% | −1.9% | +11.1% | +2.9% | +4.5% | −7.8% | −1.4% | −9.2% |
| 2023 | +7.0% | −5.9% | −0.4% | −0.3% | −2.4% | −8.4% | +1.2% | −0.8% | +17.5% | −12.7% | −9.5% | +11.6% |
| 2022 | −18.3% | −3.9% | −6.1% | −15.0% | −3.2% | −2.5% | +16.1% | +2.3% | +2.4% | +5.0% | −9.7% | −7.1% |
| 2021 | +5.0% | +12.4% | −4.4% | +0.5% | −6.0% | +5.2% | −7.9% | +15.5% | −3.7% | −3.5% | −7.9% | −4.1% |
| 2020 | −6.4% | −0.2% | +13.9% | +14.6% | −12.2% | +1.1% | +0.3% | +6.3% | +16.2% | +1.0% | +0.6% | −3.7% |
| 2019 | — | — | — | — | — | — | — | — | +18.3% | +6.2% | −9.2% | −1.3% |
GNOM Risk
Risk measures from monthly returns over Jun 2023 – May 2026.
- 3-year volatility (annualised): 28.86%
- 3-year Sharpe ratio: -0.12 (vs 4.5% risk-free rate)
- Best month: +17.49% (Sep 2023)
- Worst month: −13.29% (Apr 2024)
GNOM Fund Flows
Monthly money in and out of Global X Genomics & Biotechnology ETF, from SEC Form N-PORT.
- 12-month net flow: −$8.1M
- 12-month gross sales (incl. reinvestments): $8.8M
- Sales ÷ redemptions: 0.52×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| May 2026 | $2.1M | $828K | $1.3M |
| Apr 2026 | $0 | $0 | $0 |
| Mar 2026 | $6.6M | $6.5M | $52K |
| Feb 2026 | $0 | $1.9M | −$1.9M |
| Jan 2026 | $0 | $1.9M | −$1.9M |
| Dec 2025 | $0 | $0 | $0 |
| Nov 2025 | $661 | $1.2M | −$1.2M |
| Oct 2025 | $0 | $0 | $0 |
| Sep 2025 | $0 | $2.1M | −$2.1M |
| Aug 2025 | $84K | $0 | $84K |
| Jul 2025 | $0 | $2.4M | −$2.4M |
| Jun 2025 | $0 | $0 | $0 |
GNOM Assets Under Management
Net assets of Global X Genomics & Biotechnology ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-05-31 | $55.79M |
| 2026-02-28 | $52.38M |
| 2025-11-30 | $54.53M |
| 2025-08-31 | $46.07M |
| 2025-05-31 | $41.02M |
| 2025-02-28 | $61.76M |
| 2024-11-30 | $79.16M |
| 2024-08-31 | $84.80M |
| 2024-05-31 | $92.72M |
| 2024-02-29 | $98.81M |
| 2023-11-30 | $93.03M |
| 2023-08-31 | $146.03M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.